Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Flaherty on the Significance of the NCI-MATCH Precision Medicine Trial

December 5th 2020

Keith T. Flaherty, MD, discusses the significance of the NCI-MATCH study.

Dr. Olopade on Moving the Needle Forward in Preventive Oncology and Genetics

December 5th 2020

Olufunmilayo I. Olopade, MD, FACP, discusses the need to focus efforts in preventive oncology and genetics.

Understanding Biomarker Differences Becomes Critical as Precision Medicine Rises in Melanoma

December 4th 2020

Jason J. Luke, MD, FACP discusses the role of precision medicine and how it continues to lead the way in all areas of oncology, but especially in melanoma.

Huntsman Homes in on the Integration of Precision Medicine in Oncology

December 3rd 2020

In our exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in the field of oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.

Need for Genetic Testing Becomes More Pronounced in Breast, Gynecologic Cancers as Targeted Approaches Abound

December 2nd 2020

Lan G. Coffman, MD, PhD, discusses the role of genetic testing in breast and gynecologic cancers and the many advances made with targeted therapies.

Novel Tubulin-Targeting Therapies Make Headway

November 30th 2020

Clinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and plinabulin.

FDA Approves Naxitamab-gqgk for Relapsed/Refractory High-Risk Neuroblastoma

November 25th 2020

The FDA has approved naxitamab-gqgk (Danyelza) for use in combination with granulocyte-macrophage colony-stimulating factor as a treatment for pediatric patients 1 year of age and older and adult patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior treatment.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

Oxnard on Opening the Door for Precision Medicine in Lung Cancer

November 23rd 2020

In our exclusive interview, Dr. Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.

Blood-Based Methylation Assay Enables Early, Accurate Detection of Solid Tumors

November 20th 2020

The noninvasive blood-based targeted methylation assay ELSA-seq identified early cancers with high specificity and provided accurate predictions of the tissue of origin.

Lorlatinib Data Published in NEJM Underscore Benefits Over Crizotinib in ALK+ NSCLC

November 19th 2020

November 19, 2020 - Lorlatinib has been found to significantly prolong progression-free survival, elicit a higher overall and intracranial response, and improve quality of life compared with crizotinib in treatment-naïve patients with advanced ALK-positive non–small cell lung cancer.

Real-World Impact of Low-Grade AEs Needs a Closer Look

November 18th 2020

Although PARP inhibitors are generally reasonably well tolerated, certainly compared with platinum and other routinely employed cytotoxic antineoplastic drugs, the majority of patients receiving PARP inhibitors in multiple reported clinical trials reported low-grade nausea and fatigue.

NRG1 Fusions Hold Promise as Pan-tumor Target

November 17th 2020

The identification of chromosomal rearrangements that result in oncogenic gene fusions ushered in the era of molecularly targeted therapies in oncology.

FDA Approves PD-L1 IHC 22C3 pharmDx as Companion Diagnostic for Pembrolizumab in TNBC

November 16th 2020

November 16, 2020 — The FDA has approved the PD-L1 IHC 22C3 pharmDx to aid in the identification of patients with triple-negative breast cancer who are eligible to receive the PD-1 inhibitor pembrolizumab.

Saba Speaks to Tipifarnib and Targeting HRAS in Head and Neck Cancer

November 12th 2020

In our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.

Uncovering TP53 Mutations in MDS, AML Requires NGS

November 12th 2020

TP53-targeted treatment options represent an unmet need for patients with myelodysplastic syndromes and acute myeloid leukemia.

Initial Data from NCI-MATCH Spotlight the Growing Need for Precision Medicine in Oncology

November 11th 2020

Keith T. Flaherty, MD, discusses the rationale to conduct the NCI-MATCH trial, key findings from the recent publication, and potential permutations of the trial design that could further the role of precision medicine in oncology.

Adagrasib Shows Early Efficacy in KRAS G12C-Mutant NSCLC and CRC

November 11th 2020

Adagrasib, a novel agent aimed at KRAS G12C mutations, has demonstrated early signs of efficacy in patients with advanced non–small cell lung cancer and colorectal cancer whose tumors harbor the alteration, raising hopes for a new therapy against a challenging oncogenic target.

MET, RET, and TRK Inhibitors Achieve Standard-of-Care Status in Lung Cancer

November 9th 2020

Alterations in MET, RET, and NTRK have become established actionable drivers of oncogenesis in lung cancer, and therapeutics targeting these aberrations have since obtained regulatory approval from the FDA and have been incorporated into treatment guidelines.

KRAS G12C Emerges as an Actionable Alteration in NSCLC

November 9th 2020

Although historically considered to be undruggable, the KRAS G12C mutation has since emerged as an actionable alteration in the field of non–small cell lung cancer.